| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
UAMC-3203 HCl (also known as UAMC3203 hydrochloride) is a novel, potent, and selective Ferroptosis inhibitor (IC50 value =12 nM) with higher solublility and anti-inflammatory/antioxidant effects. Ferroptosis is a nonapoptotic, iron-catalyzed form of controlled necrosis that causes oxidative lipid damage to cell membranes and can be stopped by the antioxidant ferrostatin-1 (Fer-1). Despite having solubility problems, new inhibitors derived from the Fer-1 scaffold effectively inhibited ferroptosis. After daily injections of UAMC-3203 for 4 weeks, no toxic effects were seen in mice. According to the current understanding of these compounds' mechanisms of action, UAMC-3203 integrates quickly into a phospholipid bilayer in silico. In conclusion, these analogs outperform Fer-1 in terms of properties, exhibit efficacy in vivo, and represent novel lead compounds with therapeutic potential in pertinent ferroptosis-driven disease models.
| Targets |
Ferroptosis (IC50 = 12 nM)
|
|---|---|
| ln Vivo |
Repeated injection of UAMC-3203 (20μ mol/kg; Injected intraperitoneally; After daily, over a period of 4 weeks), no toxic reaction was observed in mice [1].
|
| References |
| Molecular Formula |
C25H38CLN5O2S
|
|---|---|
| Molecular Weight |
508.119523525238
|
| Exact Mass |
507.243
|
| Elemental Analysis |
C, 59.10; H, 7.54; Cl, 6.98; N, 13.78; O, 6.30; S, 6.31
|
| CAS # |
2271358-65-5
|
| Related CAS # |
UAMC-3203;2271358-64-4
|
| PubChem CID |
137701964
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
652
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WBZHHIZXEXJBSM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H37N5O2S.ClH/c31-33(32,28-15-18-30-16-13-26-14-17-30)23-11-12-24(29-22-9-5-2-6-10-22)25(19-23)27-20-21-7-3-1-4-8-21;/h1,3-4,7-8,11-12,19,22,26-29H,2,5-6,9-10,13-18,20H2;1H
|
| Chemical Name |
3-(benzylamino)-4-(cyclohexylamino)-N-(2-piperazin-1-ylethyl)benzenesulfonamide;hydrochloride
|
| Synonyms |
UAMC3203; UAMC-3203 HCl; UAMC 3203; UAMC-3203 hydrochloride; UAMC-3203 HCl
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~98.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9680 mL | 9.8402 mL | 19.6804 mL | |
| 5 mM | 0.3936 mL | 1.9680 mL | 3.9361 mL | |
| 10 mM | 0.1968 mL | 0.9840 mL | 1.9680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA